Expert Insights

Videos

Dual RAS Inhibition Demonstrates Promising Activity in KRAS G12D-Mutated Metastatic Pancreatic Cancer

07/23/2026

Nilofer Azad, MD, discusses results from a phase 1 study evaluating zoldonrasib plus daraxonrasib in patients with previously treated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma, highlighting encouraging preliminary...

Nilofer Azad, MD, discusses...

07/23/2026

Oncology

Videos

Biomarker-Guided Therapy May Improve Treatment Selection in Hepatocellular Carcinoma

07/22/2026

Arndt Vogel, MD

Arndt Vogel, MD, discusses results from the phase 2 IMMUNIB trial showing that first-line lenvatinib plus nivolumab demonstrated encouraging clinical activity in unresectable hepatocellular carcinoma while exploratory biomarker analyses...

Arndt Vogel, MD, discusses...

07/22/2026

Oncology

Videos

Long-Term Results Support De-escalated Neoadjuvant Therapy in HER2-Positive Breast Cancer

07/22/2026

Paolo Tarantino, MD, PhD

Paolo Tarantino, MD, PhD, discusses 5-year results from the phase 2 DAPHNe trial showing that neoadjuvant paclitaxel, trastuzumab, and pertuzumab achieved excellent long-term outcomes with no distant recurrences among patients with...

Paolo Tarantino, MD, PhD,...

07/22/2026

Oncology

Videos

MRI-Guided Adaptive Radiotherapy Safely Reduces Treatment Margins in Glioblastoma

07/16/2026

Jay Detsky, MD, PhD

Jay Detsky, MD, PhD, discusses results from the phase 2 UNITED trial showing that MRI-guided adaptive radiotherapy safely reduced treatment margins while maintaining tumor control in patients with newly diagnosed glioblastoma, supporting...

Jay Detsky, MD, PhD, discusses...

07/16/2026

Oncology

Videos

IDO1 Inhibition Combined With Radiotherapy and Nivolumab Demonstrates Safety in Newly Diagnosed Glioblastoma

07/15/2026

Rimas Lukas, MD

Rimas Lukas, MD, discusses results from a phase 1 study showing that the IDO1 inhibitor BMS-986205 combined with radiotherapy and nivolumab demonstrated a manageable safety profile and established a recommended phase 2 dose in patients with...

Rimas Lukas, MD, discusses...

07/15/2026

Oncology

Videos

Intratumoral Phosphorus-32 Enhances FOLFIRINOX in Locally Advanced Pancreatic Cancer

07/15/2026

Michele Milella, MD

Michele Milella, MD, discusses results from the phase 2 TRIPP-FFX trial showing that intratumoral phosphorus-32 microparticle implantation combined with FOLFIRINOX achieved high local disease control and encouraging tumor responses in...

Michele Milella, MD, discusses...

07/15/2026

Oncology

Videos

MonumenTAL-3 Demonstrates Superior Outcomes With Talquetamab-Based Combinations in Relapsed Multiple Myeloma

07/15/2026

Peter Voorhees, MD

Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...

Peter Voorhees, MD, discusses...

07/15/2026

Oncology

Videos

Real-World Neoadjuvant Immunotherapy Demonstrates High Response Rates in dMMR/MSI Colorectal Cancer

07/14/2026

Annalice Gandini

Annalice Gandini, IRCCS, discusses results from the real-world AGEO-NEO-MSI study which demonstrated that neoadjuvant immunotherapy produced high complete response rates in patients with nonmetastatic dMMR/MSI-H colorectal cancer while...

Annalice Gandini, IRCCS,...

07/14/2026

Oncology

Podcasts

Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma

07/08/2026

Umberto Vitolo, MD

Umberto Vitolo, MD, discusses results from the phase 3 FrontMIND trial showing that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-risk diffuse large B-cell...

Umberto Vitolo, MD, discusses...

07/08/2026

Oncology

Podcasts

How is ctDNA MRD Testing Used in Lymphoma Care?

07/06/2026

David Russler-Germain, MD, PhD

This podcast examines the clinical utility of ctDNA-based MRD testing in diffuse large B-cell lymphoma, focusing on its role in post-treatment risk stratification, relapse detection, and treatment decision-making. Dr David Russler-Germain...

This podcast examines the...

07/06/2026

Oncology

Recent News

News

Inotuzumab Ozogamicin Demonstrates High Response Rates in Pediatric Patients With Very High-Risk First Relapse B-Cell Acute Lymphoblastic Leukemia

07/24/2026

Emily Estrada

Results from cohort 3 of the phase 1/2 ITCC-059 trial demonstrated that inotuzumab ozogamicin produced high response rates with a manageable safety profile in pediatric patients with very high-risk first relapse of B-cell acute lymphoblastic...

Results from cohort 3 of the...

07/24/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

07/23/2026

Stephanie Holland

The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...

The FDA accepted for review a...

07/23/2026

Oncology

News

Phase 3 MonumenTAL-6 Trial Demonstrates Significant Survival Benefit With Dual-Bispecific Immunotherapy in Relapsed or Refractory Multiple Myeloma

07/23/2026

Stephanie Holland

Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...

Results from the phase 3...

07/23/2026

Oncology

News

Magrolimab Plus Azacitidine Fails to Improve Outcomes in Higher-Risk Myelodysplastic Syndromes

07/22/2026

Stephanie Holland

The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...

The phase 3 ENHANCE trial...

07/22/2026

Oncology

News

Consolidative Thoracic Radiotherapy Increases Toxicity Without Survival Benefit in Extensive-Stage Small Cell Lung Cancer

07/22/2026

Stephanie Holland

Results from the phase 2 TREASURE trial demonstrated that adding consolidative thoracic radiotherapy to atezolizumab maintenance increased toxicity without improving survival in patients with extensive-stage small cell lung cancer, arguing...

Results from the phase 2...

07/22/2026

Oncology

FDA Approval

FDA Approves Zidesamtinib for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer

07/22/2026

Stephanie Holland

The FDA approved zidesamtinib for adults with previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer based on findings from the phase 1/2 ARROS-1 trial demonstrating durable responses, including in patients...

The FDA approved zidesamtinib...

07/22/2026

Oncology

News

Alpha DaRT® Plus Pembrolizumab Achieves 100% Response Rate in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/21/2026

Stephanie Holland

Results from a prospective study demonstrated that Alpha DaRT® combined with pembrolizumab achieved a 100% systemic objective response rate among evaluable patients with recurrent unresectable or metastatic head and neck squamous cell...

Results from a prospective study...

07/21/2026

Oncology

News

Safusidenib Demonstrates Durable Responses and Prolonged Disease Control in Grade 2 IDH1-Mutant Glioma

07/21/2026

Emily Estrada

Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...

Updated findings from the phase...

07/21/2026

Oncology

News

Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma

07/16/2026

Stephanie Holland

Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...

Results from the phase 3...

07/16/2026

Oncology

News

Dostarlimab Meets Primary End Point in Registrational AZUR-1 Trial for dMMR/MSI-H Rectal Cancer

07/16/2026

Stephanie Holland

Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...

Interim results from the...

07/16/2026

Oncology